AdipoGen Life Sciences

anti-TLR9 (mouse), mAb (ABM4D70)

CHF 390.00
In stock
AG-20T-0309-C100100 µgCHF 390.00
More Information
Product Details
Synonyms Toll-like Receptor 9; CD289
Product Type Monoclonal Antibody
Properties
Clone ABM4D70
Isotype Rat IgG2aκ
Immunogen/Antigen Recombinant mouse TLR9 protein (aa 602-860).
Application

Flow Cytometry: (0.5-1μg/106 cells)
Western Blot: (2-4μg/ml)
Optimal conditions must be determined individually for each application.

Crossreactivity Mouse
Specificity

Recognizes mouse TLR9.

Purity Protein G purified.
Concentration 0.5mg/ml
Formulation Liquid. In PBS containing 0.05% BSA and 0.05% sodium azide.
Isotype Negative Control

Rat IgG2a Isotype Control

Accession Number Q99MB1
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice After opening, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
Stable for at least 6 months after receipt when stored at +4°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Description

TLR9 (Toll-like Receptor 9) is a member of the TLR (Toll-like receptor) family that plays a fundamental role in pathogen recognition and activation of innate immunity. TLR9 is expressed by numerous cells of the immune system such as B lymphocytes, monocytes, natural killer (NK) cells and plasmacytoid dendritic cells. It is expressed intracellularly, within the endosomal compartments and functions to alert the immune system of viral and bacterial infections by binding to DNA rich in CpG motifs. This nucleotide-sensing TLR is activated by unmethylated cytidine-phosphate-guanosine (CpG) dinucleotides (also called oligodinucleotides, ODNs), and consequently signals via MYD88 and TRAF6, leading to NF-κB activation, cytokine secretion and the inflammatory response and eventually activation of a Th1-biased adaptive immune attack. Specific TLR9 agonists have been shown to have substantial antitumor activity, making the TLR9 signaling pathway an interesting target for therapeutic research.

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.